New oral pill HPP737 aims to clear psoriasis in phase II trial
NCT ID NCT07707141
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests whether an oral drug called HPP737 can safely improve moderate-to-severe plaque psoriasis in adults. Participants take either HPP737 or a placebo daily for 85 days. Researchers measure skin improvement using standard scoring tools and track any side effects. The study aims to see if HPP737 helps achieve at least a 75% reduction in psoriasis severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an oral drug called HPP737 (also known as Prifemilast)
- What this could lead to
- If successful, this could offer a new oral treatment option for people with moderate-to-severe plaque psoriasis, potentially reducing skin symptoms.
- What could go wrong
- This is an early Phase II trial with a small number of participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Beijing Tsinghua Changgung Hospital
Beijing, China
-
Hong Kong University Shenzhen Hospital
Shenzhen, China
-
Hospital of Dermatology, Chinese Academy of Medical Sciences
Nanjing, China
-
Lianyungang First People's Hospital
Lianyungang, China
-
Shandong Provincial Hospital of Dermatology
Jinan, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
Wuxi Second People's Hospital
Wuxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill quiet the immune attack behind psoriasis?
- Laser boost for stubborn psoriasis on hands and feet
- New oral pill HPP737 takes on psoriasis in Head-to-Head trial
- New oral pill HPP737 aims to clear psoriasis in phase 3 trial
- Psoriasis Patients' quality of life under the microscope
- Skin disease evolution under the microscope: a 17-Year look at what drives severity